ALK (D5F3 ®) XP ® Rabbit mAb from Cell Signaling Technology

The ALK (D5F3 ®) XP ® Rabbit mAb has been utilized in studies involving non-small cell lung cancer (NSCLC) and thyroid cancer, particularly in the context of EML4-ALK gene fusions. For instance, research has shown its application in targeting EML4-ALK gene fusion variant 3 in thyroid cancer, highlighting its relevance in personalized medicine approaches for this malignancy (aydemirl2021).

The ALK antibody has been instrumental in elucidating mechanisms of drug resistance in cancers driven by EML4-ALK fusions. For example, studies have demonstrated that EML4-ALK assemblies can sequester receptor tyrosine kinase adapter proteins, thereby suppressing signaling pathways that are critical for drug response. Inhibition of ALK can release these adapters, leading to resensitization of signaling pathways and highlighting potential combination therapy strategies to overcome resistance (gonzalez2024).

Yes, the ALK antibody is particularly relevant for various EML4-ALK variants, including variant 3, which has been associated with aggressive tumor behavior and poor responses to conventional ALK inhibitors. Research indicates that different EML4-ALK variants exhibit differential responses to treatment, making the antibody a valuable tool for studying these variants in the context of targeted therapies (papageor2024).

The ALK antibody has been shown to be involved in inducing immunogenic cell death in anaplastic large cell lymphoma, where specific ALK inhibitors like crizotinib and ceritinib can trigger immune responses that enhance the efficacy of cancer treatments. This suggests that the ALK antibody could be useful in studies aimed at understanding and enhancing the immunogenicity of ALK-positive tumors (petrazzu2021).